New approval for ultra-rare blood cancer highlights the growing role of precision therapies in treating age-related disease.
One of the greatest challenges in longevity is ensuring people can survive the diseases that become more common with age. Cancer remains one of the biggest obstacles to extending healthy lifespan, and while much of the spotlight falls on common cancers, patients with rare malignancies are often left with few options and little attention.
That’s what makes the US Food and Drug Administration’s (FDA) recent approval of DECNUPAZ (pivekimab sunirine-pvzy) noteworthy.
The new therapy from AbbVie has been approved for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and highly aggressive blood cancer that primarily affects older adults, particularly men between the ages of 60 and 70 [1]. Beyond giving patients a new treatment option, the approval also strengthens AbbVie’s growing blood cancer portfolio and underscores a broader shift taking place in oncology: the move toward increasingly precise, targeted therapies.
BPDCN is rare enough that many physicians may encounter only a handful of cases throughout their careers. The disease often begins with unusual skin lesions that can appear deceptively harmless. Beneath the surface, however, BPDCN can move quickly, spreading into the bone marrow, lymph nodes and central nervous system. Historically, treatment has relied on intensive chemotherapy and, for some patients, stem cell transplantation.
The challenge is that even when patients initially respond, the cancer frequently returns. For a disease with such limited treatment options, each new therapeutic advance carries outsized importance.
“For patients living with rare cancers, progress in research can be life-changing,” said Roopal Thakkar, executive vice president, research and development, chief scientific officer of AbbVie. “This approval delivers a new option for treating BPDCN and demonstrates our determination to drive meaningful advancements for patients affected by difficult-to-treat cancers.”
What makes DECNUPAZ particularly interesting is the type of medicine it represents. The therapy belongs to a rapidly growing class of cancer drugs known as antibody-drug conjugates (ADCs).
Traditional chemotherapy can be compared to using a sprinkler system to put out a fire. It can be effective, but healthy tissues often get caught in the crossfire. ADCs are designed to act more like guided delivery systems, carrying a powerful cancer-killing agent directly to cells displaying a specific biological marker.
In BPDCN, that marker is a protein called CD123, which appears in unusually high levels on cancer cells. DECNUPAZ uses that marker almost like a postal address, helping deliver treatment where it’s needed most.
The approval also marks a first for AbbVie. DECNUPAZ is the company’s first antibody-drug conjugate approved for a blood cancer and the first approved ADC for BPDCN that can be initiated in an outpatient setting.
“BPDCN is an aggressive disease with historically limited therapeutic options, particularly for patients whose disease has relapsed or become refractory,” said Dr Naveen Pemmaraju, professor of leukemia at The University of Texas MD Anderson Cancer Center. “Pivekimab sunirine-pvzy is the first and only CD123 targeting ADC that can be initiated in an outpatient setting, offering a meaningful benefit for BPDCN patients in need of new treatment alternatives.”
The FDA’s decision was supported by results from the Phase 1/2 CADENZA study. Among newly diagnosed patients, nearly 70% achieved a complete or near-complete response to treatment. Those responses lasted a median of almost 10 months, and approximately four in ten patients were able to move on to stem cell transplantation following treatment.
Patients whose cancer had already relapsed or stopped responding to previous therapies saw lower response rates, which is not unusual in advanced disease. Still, researchers reported responses lasting more than nine months on average in a population where treatment options remain scarce.
As with most cancer therapies, the benefits come alongside risks. Common side effects included fluid retention, fatigue, pain, nausea and diarrhea. The drug also carries a boxed warning related to potentially serious liver complications, meaning careful monitoring will remain an important part of treatment.
The approval arrives at a moment when antibody-drug conjugates have become one of the most closely watched areas in biotechnology. Large pharma companies and investors have poured billions into ADC development over the past several years.
For AbbVie, DECNUPAZ adds another piece to an increasingly broad blood cancer portfolio that already includes therapies for leukemia, lymphoma and multiple myeloma. Just weeks after the FDA approval, the company presented additional data across its hematologic cancer programs at the European Hematology Association Congress [2].
While BPDCN itself affects relatively few people, the scientific lessons learned from treating rare cancers often ripple far beyond a single disease. Many of today’s precision oncology breakthroughs began in small patient populations before influencing treatment strategies across much larger cancer markets.
In longevity circles, cancer is often discussed as one of the major biological barriers to extending healthy lifespan, yet the conversation frequently focuses on prevention and early detection.
Treatment innovation deserves equal attention. As populations age, the number of people living with cancer is expected to rise. Extending healthspan will depend not only on delaying disease but also on developing smarter ways to treat it when it occurs.
That is why approvals like DECNUPAZ matter beyond their immediate patient population. They reflect a future in which medicine becomes increasingly precise, matching therapies to the biology of individual diseases rather than relying solely on broad, one-size-fits-all approaches.
For patients with BPDCN, the FDA’s decision means access to a much-needed new option. For the broader longevity field, it is another reminder that progress often arrives incrementally – one rare disease, one targeted therapy and one regulatory milestone at a time.
[1] https://news.abbvie.com/2026-05-27-U-S-FDA-Approves-DECNUPAZTM-pivekimab-sunirine-pvzy-for-Treatment-of-Adult-Patients-with-Blastic-Plasmacytoid-Dendritic-Cell-Neoplasm,-an-Ultra-Rare-and-Aggressive-Blood-Cancer-With-Limited-Treatment-Options
[2] https://news.abbvie.com/2026-06-08-AbbVie-Presents-New-Data-Across-Its-Blood-Cancer-Portfolio-at-EHA-2026
